New hope for kids with hard-to-treat genetic seizures
NCT ID NCT05818553
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medicine called PRAX-562 in 77 children with rare genetic epilepsies (SCN2A or SCN8A). The goal is to see if it safely reduces motor seizures. The trial has two parts: a double-blind phase where some children get the drug and some get a placebo, followed by an open-label phase where all children can receive the drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCN2A ENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Praxis Research Site
Atlanta, Georgia, 30329, United States
-
Praxis Research Site
Chicago, Illinois, 60611, United States
-
Praxis Research Site
Minneapolis, Minnesota, 55113, United States
-
Praxis Research Site
Hackensack, New Jersey, 07601, United States
-
Praxis Research Site
Tel Litwinsky, 52621, Israel
-
Praxis Research Site
Madrid, 28034, Spain
-
Praxis Research Site
Glasgow, G51 4TF, United Kingdom
-
Praxis Research Site
London, WC1N 3BH, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.